Skip to main content
Erschienen in: Indian Journal of Surgery 5/2016

23.04.2016 | Original Article

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

verfasst von: Aynur Ozen, Serdar Altinay, Ozgul Ekmekcioglu, Ramazan Albayrak, Ali Muhammedoglu, Hakan Yigitbas, Eylem Bastug, Atilla Celik

Erschienen in: Indian Journal of Surgery | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

The aims of this retrospective study were to consider the diagnostic role of dual-time 18F-fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET/CT) in detection of breast carcinoma and axillary lymph node (ALN) status and to evaluate the primary tumor 18F-FDG uptake pattern. Preoperative staging was performed by 18F-FDG PET/CT in 78 female patients with breast carcinoma. Conventional imaging results were evaluated by breast magnetic resonance imaging (MRI) of 79 lesions in 78 patients, bilateral mammography (MMG) of 40 lesions in 40 patients, and breast ultrasonography (USG) of 47 lesions in 46 patients. The primary tumor detection rate using 18F-FDG PET/CT was higher than those using MRI, USG, and MMG. The sensitivity and specificity of 18F-FDG PET/CT scans for detecting multifocality were higher than those of MRI. The specificity of ALN metastasis detection with MRI was higher than that with 18F-FDG PET/CT, but 18F-FDG PET/CT had higher sensitivity. Higher 18F-FDG uptake levels were detected in patients with ALN metastasis, histologic grade 3, estrogen–progesterone-negative receptor status, lymphatic invasion, and moderate to poor prognostic groups. There was no statistical difference for the retention index in categorical pathological parameters except for progesterone-negative status. In conclusion, 18F-FDG PET/CT scans may be a valuable imaging technique for evaluating primary tumor and axillary status in staging breast carcinoma and 18F-FDG uptake may be a prognostic factor that indicates aggressive tumor biology and poor prognosis. Dual-time imaging in breast carcinoma staging may not be used for predicting pathological criteria and the aggressiveness of primary lesions.
Literatur
1.
Zurück zum Zitat Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE (2009) Breast cancer screening and diagnosis. J Natl Compr Cancer Netw 7:1060–1096 Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE (2009) Breast cancer screening and diagnosis. J Natl Compr Cancer Netw 7:1060–1096
2.
Zurück zum Zitat Abdulkareem ST (2014) Breast magnetic resonance imaging indications in current practice. Asian Pac J Cancer Prev 15:569–575PubMedCrossRef Abdulkareem ST (2014) Breast magnetic resonance imaging indications in current practice. Asian Pac J Cancer Prev 15:569–575PubMedCrossRef
3.
Zurück zum Zitat Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P (2007) Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 14:549–567. doi:10.1677/ERC-06-0060 PubMedCrossRef Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P (2007) Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 14:549–567. doi:10.​1677/​ERC-06-0060 PubMedCrossRef
4.
Zurück zum Zitat Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22–30PubMedCrossRef Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22–30PubMedCrossRef
5.
Zurück zum Zitat Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK (2010) Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 17(Suppl 3):343–351. doi:10.1245/s10434-010-1253-3 PubMedPubMedCentralCrossRef Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK (2010) Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 17(Suppl 3):343–351. doi:10.​1245/​s10434-010-1253-3 PubMedPubMedCentralCrossRef
6.
7.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. doi:10.1200/JCO.2009.25.6529 PubMedPubMedCentralCrossRef Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. doi:10.​1200/​JCO.​2009.​25.​6529 PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56:37–47PubMedCrossRef Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56:37–47PubMedCrossRef
10.
Zurück zum Zitat Garami Z, Hascsi Z, Varga J, Dinya T, Tanyi M, Garai I, Damjanovich L, Galuska L (2012) The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol 38:31–37. doi:10.1016/j.ejso.2011.09.002 PubMedCrossRef Garami Z, Hascsi Z, Varga J, Dinya T, Tanyi M, Garai I, Damjanovich L, Galuska L (2012) The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol 38:31–37. doi:10.​1016/​j.​ejso.​2011.​09.​002 PubMedCrossRef
11.
Zurück zum Zitat Dong G, Wang D, Liang X, Gao H, Wang L, Yu X, Liu J (2014) Factors related to survival rates for breast cancer patients. Int J Clin Exp Med 7:3719–3724PubMedPubMedCentral Dong G, Wang D, Liang X, Gao H, Wang L, Yu X, Liu J (2014) Factors related to survival rates for breast cancer patients. Int J Clin Exp Med 7:3719–3724PubMedPubMedCentral
13.
Zurück zum Zitat Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, Kimmig KR, Forsting M, Bockisch A, Antoch G, Stahl A (2009) Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 36:1543–1550. doi:10.1007/s00259-009-1145-6 PubMedCrossRef Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, Kimmig KR, Forsting M, Bockisch A, Antoch G, Stahl A (2009) Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 36:1543–1550. doi:10.​1007/​s00259-009-1145-6 PubMedCrossRef
14.
Zurück zum Zitat Reddy CV, Srivastava A (2009) Role of FDG PET-CT in evaluation of axillary lymph node involvement in T1T2N0 breast cancer in comparison with sentinel lymph node biopsy. J Nucl Med 50(Supplement 2):1691–1691 Reddy CV, Srivastava A (2009) Role of FDG PET-CT in evaluation of axillary lymph node involvement in T1T2N0 breast cancer in comparison with sentinel lymph node biopsy. J Nucl Med 50(Supplement 2):1691–1691
15.
Zurück zum Zitat Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S (2004) Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 130:273–278. doi:10.1007/s00432-003-0536-5 PubMedCrossRef Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S (2004) Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 130:273–278. doi:10.​1007/​s00432-003-0536-5 PubMedCrossRef
16.
Zurück zum Zitat Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K (2013) Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun 34:1055–1067. doi:10.1097/MNM.0b013e3283658369 PubMedCrossRef Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K (2013) Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun 34:1055–1067. doi:10.​1097/​MNM.​0b013e3283658369​ PubMedCrossRef
17.
Zurück zum Zitat Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K, Tanaka M (2007) Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 73:1151–1157PubMed Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K, Tanaka M (2007) Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 73:1151–1157PubMed
18.
Zurück zum Zitat Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H (2008) Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38:250–258. doi:10.1093/jjco/hyn019 PubMedCrossRef Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H (2008) Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38:250–258. doi:10.​1093/​jjco/​hyn019 PubMedCrossRef
19.
Zurück zum Zitat Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W, Waisman JR, Silverstein MJ (2002) Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg 184:337–340PubMedCrossRef Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W, Waisman JR, Silverstein MJ (2002) Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg 184:337–340PubMedCrossRef
20.
Zurück zum Zitat Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435. doi:10.1007/s00259-010-1640-9 PubMedCrossRef Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435. doi:10.​1007/​s00259-010-1640-9 PubMedCrossRef
21.
Zurück zum Zitat Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T (2010) Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 15:588–593. doi:10.1007/s10147-010-0120-3 PubMedCrossRef Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T (2010) Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 15:588–593. doi:10.​1007/​s10147-010-0120-3 PubMedCrossRef
22.
Zurück zum Zitat Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, Ueno M, Koriyama C, Nakajo M (2010) FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 37:2011–2020. doi:10.1007/s00259-010-1529-7 PubMedCrossRef Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, Ueno M, Koriyama C, Nakajo M (2010) FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 37:2011–2020. doi:10.​1007/​s00259-010-1529-7 PubMedCrossRef
23.
Zurück zum Zitat Elston CW, Ellis IO, Pinder SE (1999) Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 31:209–223PubMedCrossRef Elston CW, Ellis IO, Pinder SE (1999) Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 31:209–223PubMedCrossRef
24.
Zurück zum Zitat Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, Bender HG, Mueller-Gaertner HW (1999) Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 26:226–230PubMedCrossRef Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, Bender HG, Mueller-Gaertner HW (1999) Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 26:226–230PubMedCrossRef
25.
Zurück zum Zitat García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Muñoz Madero V, Molina Garrido MJ, León Martín AA, Cordero García JM, Pilkington Woll JP, Chacón López-Muñiz I, Palomar Muñoz A (2012) 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. Rev Esp Med Nucl Imagen Mol 31:308–314. doi:10.1016/j.remn.2011.12.001 PubMed García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Muñoz Madero V, Molina Garrido MJ, León Martín AA, Cordero García JM, Pilkington Woll JP, Chacón López-Muñiz I, Palomar Muñoz A (2012) 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. Rev Esp Med Nucl Imagen Mol 31:308–314. doi:10.​1016/​j.​remn.​2011.​12.​001 PubMed
Metadaten
Titel
Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors
verfasst von
Aynur Ozen
Serdar Altinay
Ozgul Ekmekcioglu
Ramazan Albayrak
Ali Muhammedoglu
Hakan Yigitbas
Eylem Bastug
Atilla Celik
Publikationsdatum
23.04.2016
Verlag
Springer India
Erschienen in
Indian Journal of Surgery / Ausgabe 5/2016
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-016-1486-x

Weitere Artikel der Ausgabe 5/2016

Indian Journal of Surgery 5/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.